CervoMed Inc. Common Stock (CRVO) — Analysis Summary
CervoMed Inc. Common Stock (CRVO) has a market cap of $37.95M with year-over-year revenue growth of -58.9%. Net margin stands at -673.1%. The stock trades at a P/E ratio of -1.3.
Key Takeaways
- Revenue changed -58.9% year-over-year
- Net margin of -673.1%
- P/E ratio of -1.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CRVO posted revenue growth of -58.9% and trades at a P/E of -1.3.
CervoMed Inc. Common Stock (CRVO)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -9407.0% — severe operating losses
Net margin at -9160.9% — losses exceed revenue (possible one-time charges)
Revenue fell 91.7% vs the prior period.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
15
Headquarters
BOSTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.